Security
Carlsmed, Inc. Common Stock · CARL
CARLNASDAQCommon stockCurrentCIK 1794546Updated Oct 7, 2026
CARL price & chart
Loading TradingView…
NASDAQ:CARL on TradingView ↗About the company
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
In the news
Carlsmed, Inc. Announces Chief Operating Officer Appointment ↗
Recent filings
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
EFFECT filing
S-3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 130,120,000Source | 51,824,000Source |
| Property, Plant and Equipment, NetUSD | 1,487,000Source | 260,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 85,793,000Source | 40,125,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 11,362,000Source | 6,766,000Source |
| Inventory, NetUSD | 1,845,000Source | 995,000Source |
| Assets, CurrentUSD | 126,673,000Source | 49,351,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,573,000Source | 1,365,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,826,000Source | 1,644,000Source |
| Other Assets, NoncurrentUSD | 134,000Source | 569,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 31,251,000Source | 26,228,000Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 0Source | 0Source |
| Additional Paid in CapitalUSD | 199,674,000Source | 541,000Source |
| Retained Earnings (Accumulated Deficit)USD | -100,805,000Source | -71,171,000Source |
| Stockholders' Equity Attributable to ParentUSD | 98,869,000Source | -70,630,000Source |
| Liabilities and EquityUSD | 130,120,000Source | 51,824,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 14,280,000Source | 8,818,000Source |
| Operating Lease, Liability, CurrentUSD | 752,000Source | 449,000Source |
| Accounts Payable, CurrentUSD | 4,481,000Source | 2,412,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,316,000Source | 1,317,000Source |
| Other Liabilities, NoncurrentUSD | 309,000Source | 222,000Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 3,287,000Source | 2,687,000Source |
| Long-term DebtUSD | 15,346,000Source | 15,414,000Source |
| Short-term InvestmentsUSD | 24,000,000Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 281,000Source | 145,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,927,000Source | 253,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts ReceivableUSD | 5,010,000Source | 3,969,000Source |
| Increase (Decrease) in InventoriesUSD | 2,689,000Source | 1,798,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,323,000Source | 297,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -28,977,000Source | -25,466,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -25,483,000Source | -180,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 642,000Source | 180,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 100,128,000Source | 58,499,000Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 1,927,000Source | 253,000Source |
| DepreciationUSD | 300,000Source | 100,000Source |
| General and Administrative ExpenseUSD | 16,568,000Source | 8,394,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Inventory Write-downUSD | 1,839,000Source | 1,378,000Source |
| Investment Income, InterestUSD | 2,698,000Source | 1,330,000Source |
| Net Income (Loss) Attributable to ParentUSD | -29,634,000Source | -24,257,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -30,218,000Source | -24,849,000Source |
| Operating ExpensesUSD | 68,614,000Source | 44,170,000Source |
| Operating Lease, ExpenseUSD | 700,000Source | 600,000Source |
| Other Nonoperating Income (Expense)USD | 940,000Source | -135,000Source |
| Proceeds from Stock Options ExercisedUSD | 205,000Source | 34,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 50,511,000Source | 27,165,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cost of Goods and Services Sold | — | — |
| Operating Income (Loss)USD | -30,574,000Source | -24,122,000Source |
| Other Nonoperating Income (Expense)USD | 940,000Source | -135,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -29,634,000Source | -24,257,000Source |
| Earnings Per Share, BasicUSD per share | -2.12Source | -6.11Source |
| Earnings Per Share, DilutedUSD per share | -2.12Source | -6.11Source |
| Total Revenue | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 14,221,991Source | 4,066,395Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 14,221,991Source | 4,066,395Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 16,568,000Source | 8,394,000Source |
| Gross ProfitUSD | 38,040,000Source | 20,048,000Source |
| Interest ExpenseUSD | 1,430,000Source | 1,321,000Source |
| Investment Income, InterestUSD | 2,698,000Source | 1,330,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -30,218,000Source | -24,849,000Source |
| Operating ExpensesUSD | 68,614,000Source | 44,170,000Source |
| Operating Lease, ExpenseUSD | 700,000Source | 600,000Source |
| Other ExpensesUSD | 24,314,000Source | 13,084,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 584,000Source | 592,000Source |
| Research and Development ExpenseUSD | 17,019,000Source | 14,304,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 50,511,000Source | 27,165,000Source |
| Selling and Marketing ExpenseUSD | 35,027,000Source | 21,472,000Source |
| Selling ExpenseUSD | 26,426,000Source | 15,550,000Source |
Offerings
Registration 333-298345
Filing attachments
carl-ex99_1.htm · 8-K · 2026-09-30
Exhibit 99.1 Carlsmed Appoints Richard Heppenstall as Chief Financial Officer Company Reaffirms Fiscal Year 2026 Guidance CARLSBAD, Calif., September 28, 2026 (GLOBE NEWSWIRE) - Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CF…
Read attachment ↗carl-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 carl-ex99_1.htm EX-99.1 EX-99.1 Carlsmed, Inc. Announces Chief Operating Officer Appointment CARLSBAD, Calif., September 8, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the…
Read attachment ↗carl-ex4_5.htm · S-3 · 2026-08-14
Exhibit 4.5 CARLSMED, INC. INDENTURE Dated as of [___], 20[__] [___] Trustee TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 5 Section 1.1. Definitions. 5 Section 1.2. Other Definitions. 8 Section 1.3. …
Read attachment ↗carl-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 carl-ex99_1.htm EX-99.1 EX-99.1 Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, CALIFORNIA, AUGUST 5, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, tod…
Read attachment ↗carl-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 carl-ex99_1.htm EX-99.1 EX-99.1 Carlsmed® Reports First Quarter 2026 Financial Results First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, CALIFORNIA, MAY 5, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for t…
Read attachment ↗